Interpreting success or failure of peanut oral immunotherapy
Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining sensitization to peanuts after cessation of treatment. It is important, therefore, to identify biomarkers that impact and predict OIT outcomes. I...
Saved in:
| Published in | The Journal of clinical investigation Vol. 132; no. 2 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Clinical Investigation
18.01.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining sensitization to peanuts after cessation of treatment. It is important, therefore, to identify biomarkers that impact and predict OIT outcomes. In this issue of the JCI, Monian, Tu, and colleagues describe distinct subsets of peanut-reactive CD4+ Th cell phenotypes and gene signatures with relevance to OIT outcomes using single-cell RNA-Seq and paired T cell receptor (TCR) α/β sequencing. The insights obtained will inform the development of therapeutics that target these Th cell phenotypes or deplete peanut-specific Th2 cells to achieve sustained nonresponsiveness in food allergy. |
|---|---|
| AbstractList | Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining sensitization to peanuts after cessation of treatment. It is important, therefore, to identify biomarkers that impact and predict OIT outcomes. In this issue of the JCI, Monian, Tu, and colleagues describe distinct subsets of peanut-reactive CD4+ Th cell phenotypes and gene signatures with relevance to OIT outcomes using single-cell RNA-Seq and paired T cell receptor (TCR) α/β sequencing. The insights obtained will inform the development of therapeutics that target these Th cell phenotypes or deplete peanut-specific Th2 cells to achieve sustained nonresponsiveness in food allergy.Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining sensitization to peanuts after cessation of treatment. It is important, therefore, to identify biomarkers that impact and predict OIT outcomes. In this issue of the JCI, Monian, Tu, and colleagues describe distinct subsets of peanut-reactive CD4+ Th cell phenotypes and gene signatures with relevance to OIT outcomes using single-cell RNA-Seq and paired T cell receptor (TCR) α/β sequencing. The insights obtained will inform the development of therapeutics that target these Th cell phenotypes or deplete peanut-specific Th2 cells to achieve sustained nonresponsiveness in food allergy. Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining sensitization to peanuts after cessation of treatment. It is important, therefore, to identify biomarkers that impact and predict OIT outcomes. In this issue of the JCI, Monian, Tu, and colleagues describe distinct subsets of peanut-reactive CD4+ Th cell phenotypes and gene signatures with relevance to OIT outcomes using single-cell RNA-Seq and paired T cell receptor (TCR) α/β sequencing. The insights obtained will inform the development of therapeutics that target these Th cell phenotypes or deplete peanut-specific Th2 cells to achieve sustained nonresponsiveness in food allergy. Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining sensitization to peanuts after cessation of treatment. It is important, therefore, to identify biomarkers that impact and predict OIT outcomes. In this issue of the JCI , Monian, Tu, and colleagues describe distinct subsets of peanut-reactive CD4 + Th cell phenotypes and gene signatures with relevance to OIT outcomes using single-cell RNA-Seq and paired T cell receptor (TCR) α/β sequencing. The insights obtained will inform the development of therapeutics that target these Th cell phenotypes or deplete peanut-specific Th2 cells to achieve sustained nonresponsiveness in food allergy. Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining sensitization to peanuts after cessation of treatment. It is important, therefore, to identify biomarkers that impact and predict OIT outcomes. In this issue of the JCI, Monian, Tu, and colleagues describe distinct subsets of peanut-reactive [CD4.sup.+] Th cell phenotypes and gene signatures with relevance to OIT outcomes using single-cell RNA-Seq and paired T cell receptor (TCR) [alpha]/[beta] sequencing. The insights obtained will inform the development of therapeutics that target these Th cell phenotypes or deplete peanut-specific Th2 cells to achieve sustained nonresponsiveness in food allergy. |
| Audience | Academic |
| Author | Cao, Shijie Nagler, Cathryn R. |
| AuthorAffiliation | 1 Pritzker School of Molecular Engineering and 2 Biological Sciences Division, University of Chicago, Chicago, Illinois, USA |
| AuthorAffiliation_xml | – name: 1 Pritzker School of Molecular Engineering and – name: 2 Biological Sciences Division, University of Chicago, Chicago, Illinois, USA |
| Author_xml | – sequence: 1 givenname: Shijie orcidid: 0000-0002-9175-0813 surname: Cao fullname: Cao, Shijie – sequence: 2 givenname: Cathryn R. orcidid: 0000-0001-7254-6617 surname: Nagler fullname: Nagler, Cathryn R. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35040441$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkl1rFDEUhoNU7Ide-AdkrsRerM3nJANSKEvVlYI3eh0ymZPdlJlkTDJC_71Zty2tXuVw8r7PeUPOKToKMQBCbwn-SIikF9_WGyIEFeIFOqmFWinK1NGT-hid5nyLMeFc8FfomAnMMefkBH3ahAJpTlB82DZ5sRZybmJqnPHjkqCJrpnBhKXUphkbP01LiGUHycx3r9FLZ8YMb-7PM_Tz8_WP9dfVzfcvm_XVzcpywcTKdZL3TnFoWcepsYwziVtpeWeFVZQQ5zCVfdsDJ6rH1EkMpmU9dEa5amZnaHPgDtHc6jn5yaQ7HY3XfxsxbbVJxdsRNO9ADG1PHVDJ244ZaYd2ANI7aRV0qrIuD6x56ScYLIRS3_UM-vwm-J3ext9aSdFJySvgwz0gxV8L5KInny2MowkQl6xpSwkmisj9rPcH6dbUaDswY9nlOC7Fx5D1VdsRLpQQrArfPQ31mObhn6rg4iCwKeacwGnri9lzakY_aoL1fhP04yZUx_k_jgfo_9o_-7uyDg |
| CitedBy_id | crossref_primary_10_3388_jspaci_38_282 crossref_primary_10_1016_j_jaci_2022_10_025 |
| Cites_doi | 10.4049/jimmunol.1700141 10.1126/science.aaw6433 10.1016/j.jaci.2010.12.1111 10.1111/all.14180 10.1016/j.jaci.2013.11.020 10.1016/j.jaci.2016.04.021 10.1172/JCI124605 10.1172/JCI150634 10.1056/NEJMoa1812856 10.3389/fimmu.2020.594350 10.1007/s11882-016-0616-7 10.1016/j.jaip.2018.10.048 10.1073/pnas.1520180113 10.1016/j.jaci.2017.12.979 10.1016/S0140-6736(19)31793-3 10.1016/j.jaci.2017.11.020 10.1016/j.jaci.2013.12.1037 10.1016/j.cell.2013.04.007 10.1038/ni.2182 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2022 American Society for Clinical Investigation 2022 Cao et al. 2022 Cao et al. |
| Copyright_xml | – notice: COPYRIGHT 2022 American Society for Clinical Investigation – notice: 2022 Cao et al. 2022 Cao et al. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1172/JCI155255 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1558-8238 |
| ExternalDocumentID | oai_doaj_org_article_49e5d6b2fe274693a7cd6de1bf7c8e98 PMC8759774 A691458553 35040441 10_1172_JCI155255 |
| Genre | Comment Journal Article |
| GroupedDBID | --- -~X .55 .XZ 08G 08P 29K 354 36B 5GY 5RE 5RS 7RV 7X7 88E 8AO 8F7 8FE 8FH 8FI 8FJ 8R4 8R5 AAWTL AAYXX ABOCM ABPMR ABUWG ACGFO ACIHN ACNCT ACPRK ADBBV AEAQA AENEX AFCHL AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ASPBG AVWKF AZFZN BAWUL BBNVY BCU BEC BENPR BHPHI BKEYQ BLC BPHCQ BVXVI CCPQU CITATION CS3 D-I DIK DU5 E3Z EBS EJD EMB EX3 F5P FRP FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IEA IHR IHW INH IOF IOV IPO ISR ITC KQ8 L7B LK8 M1P M5~ M7P NAPCQ OBH OCB ODZKP OFXIZ OGEVE OHH OK1 OVD OVIDX OVT P2P P6G PHGZM PHGZT PQQKQ PROAC PSQYO Q2X RPM S0X SJFOW SV3 TEORI TR2 TVE UKHRP VVN W2D WH7 WOQ WOW X7M XSB YFH YHG YKV YOC ZY1 ~H1 3V. 88A CGR CUY CVF ECM EIF INR M0L NPM 7X8 PPXIY PQGLB 5PM PJZUB PUEGO |
| ID | FETCH-LOGICAL-c4535-f974bf84e63942ac3437067c49c5c8211ff027b6be418b02f70ea63be9a8ff973 |
| IEDL.DBID | DOA |
| ISSN | 1558-8238 0021-9738 |
| IngestDate | Wed Aug 27 01:20:26 EDT 2025 Thu Aug 21 18:09:24 EDT 2025 Thu Jul 10 17:26:32 EDT 2025 Thu May 22 21:22:02 EDT 2025 Thu Jan 02 22:55:37 EST 2025 Tue Jul 01 00:21:53 EDT 2025 Thu Apr 24 23:12:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | http://creativecommons.org/licenses/by/4.0 This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4535-f974bf84e63942ac3437067c49c5c8211ff027b6be418b02f70ea63be9a8ff973 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Commentary-3 content type line 23 |
| ORCID | 0000-0001-7254-6617 0000-0002-9175-0813 |
| OpenAccessLink | https://doaj.org/article/49e5d6b2fe274693a7cd6de1bf7c8e98 |
| PMID | 35040441 |
| PQID | 2621018178 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_49e5d6b2fe274693a7cd6de1bf7c8e98 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8759774 proquest_miscellaneous_2621018178 gale_healthsolutions_A691458553 pubmed_primary_35040441 crossref_citationtrail_10_1172_JCI155255 crossref_primary_10_1172_JCI155255 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-18 |
| PublicationDateYYYYMMDD | 2022-01-18 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-18 day: 18 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of clinical investigation |
| PublicationTitleAlternate | J Clin Invest |
| PublicationYear | 2022 |
| Publisher | American Society for Clinical Investigation |
| Publisher_xml | – name: American Society for Clinical Investigation |
| References | Fernandez-Rivas (B2) Dolence (B9) 2018; 142 Blumchen (B7) 2019; 7 Kobayashi (B15) 2017; 139 Czolk (B17) 2021; 11 Sicherer (B5) 2014; 133 Monian (B11) 2022; 132 Luce (B18) 2020; 75 Syed (B19) 2014; 133 Liang (B13) 2011; 13 Gowthaman (B10) 2019; 365 B1 Chinthrajah (B3) 2019; 394 Iweala (B4) 2016; 16 Meli (B14) 2017; 199 Sampath (B6) 2019; 129 Ryan (B8) 2016; 113 Varshney (B20) 2011; 127 Kulis (B16) 2018; 141 Tubo (B12) 2013; 153 34813505 - J Clin Invest. 2022 Jan 18;132(2) |
| References_xml | – volume: 199 start-page: 244 issue: 1 year: 2017 ident: B14 article-title: T follicular helper cell-derived IL-4 is required for IgE production during intestinal helminth infection publication-title: J Immunol doi: 10.4049/jimmunol.1700141 – volume: 365 issue: 6456 year: 2019 ident: B10 article-title: Identification of a T follicular helper cell subset that drives anaphylactic IgE publication-title: Science doi: 10.1126/science.aaw6433 – volume: 127 start-page: 654 issue: 3 year: 2011 ident: B20 article-title: A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2010.12.1111 – volume: 75 start-page: 1513 issue: 6 year: 2020 ident: B18 article-title: Th2A and Th17 cell frequencies and regulatory markers as follow-up biomarker candidates for successful multifood oral immunotherapy publication-title: Allergy doi: 10.1111/all.14180 – volume: 133 start-page: 291 issue: 2 year: 2014 ident: B5 article-title: Food allergy: epidemiology, pathogenesis, diagnosis, and treatment publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2013.11.020 – volume: 139 start-page: 300 issue: 1 year: 2017 ident: B15 article-title: Follicular helper T cells mediate IgE antibody response to airborne allergens publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2016.04.021 – volume: 129 start-page: 1431 issue: 4 year: 2019 ident: B6 article-title: Newly identified T cell subsets in mechanistic studies of food immunotherapy publication-title: J Clin Invest doi: 10.1172/JCI124605 – volume: 132 issue: 2 year: 2022 ident: B11 article-title: Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells publication-title: J Clin Invest doi: 10.1172/JCI150634 – ident: B1 doi: 10.1056/NEJMoa1812856 – volume: 11 year: 2021 ident: B17 article-title: IgE-mediated peanut allergy: current and novel predictive biomarkers for clinical phenotypes using multi-omics approaches publication-title: Front Immunol doi: 10.3389/fimmu.2020.594350 – volume: 16 issue: 5 year: 2016 ident: B4 article-title: Food allergy: our evolving understanding of its pathogenesis, prevention, and treatment publication-title: Curr Allergy Asthma Rep doi: 10.1007/s11882-016-0616-7 – volume: 7 start-page: 479 issue: 2 year: 2019 ident: B7 article-title: Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2018.10.048 – volume: 113 start-page: E1286 issue: 9 year: 2016 ident: B8 article-title: Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1520180113 – volume: 141 start-page: 491 issue: 2 year: 2018 ident: B16 article-title: Immune mechanisms of oral immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2017.12.979 – volume: 394 start-page: 1437 issue: 10207 year: 2019 ident: B3 article-title: Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study publication-title: Lancet doi: 10.1016/S0140-6736(19)31793-3 – ident: B2 article-title: Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy publication-title: Allergy – volume: 142 start-page: 1144 issue: 4 year: 2018 ident: B9 article-title: Airway exposure initiates peanut allergy by involving the IL-1 pathway and T follicular helper cells in mice publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2017.11.020 – volume: 133 start-page: 500 issue: 2 year: 2014 ident: B19 article-title: Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3) publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2013.12.1037 – volume: 153 start-page: 785 issue: 4 year: 2013 ident: B12 article-title: Single naive CD4+ T cells from a diverse repertoire produce different effector cell types during infection publication-title: Cell doi: 10.1016/j.cell.2013.04.007 – volume: 13 start-page: 58 issue: 1 year: 2011 ident: B13 article-title: Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity publication-title: Nat Immunol doi: 10.1038/ni.2182 – reference: 34813505 - J Clin Invest. 2022 Jan 18;132(2): |
| SSID | ssj0014454 |
| Score | 2.386907 |
| SecondaryResourceType | review_article |
| Snippet | Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| SubjectTerms | Administration, Oral Arachis Desensitization, Immunologic Humans Peanut Hypersensitivity - therapy Th2 Cells |
| Title | Interpreting success or failure of peanut oral immunotherapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35040441 https://www.proquest.com/docview/2621018178 https://pubmed.ncbi.nlm.nih.gov/PMC8759774 https://doaj.org/article/49e5d6b2fe274693a7cd6de1bf7c8e98 |
| Volume | 132 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB7aFEovpe86bTdq6aEXE1tPC3rJkyQloZQG9iYkWSJbijcku4f--45kr9mlgV5ytCUbecbSzCfNfAPwuWmkpZqzUlTWldz5WFrX1qWrfNVqGmXMBKbnF_Lkkp9NxXSt1FeKCevpgXvB7XIdRCsdjQHxk9TMKt_KNtQuKt8EndN80eatwNRwfsC54AOPEFro3V9-lqjGUj7fmvXJJP3_LsVrtmgzTnLN8Bw_g6eDx0j2-pE-hwehewGPz4cz8ZfwdYwbRCtEbpe5AiKZ35BoZynmnMwjSfvtywVJ2fhkljJChryrP6_g8vjo58FJOdREKD0XTJQR_X8XGx7Qs-DUesaZQoPjufbCN4jmYkSg6aQLvG5cRaOqgpXMBW2biA-z17DVzbvwFghvJbZqFdBJ4C3CoiCCqJ20MdGX1rSALytZGT8Qhqe6Fb9NBg6KmrOD016sBXwau173LBl3ddpPAh87JGLrfAPVbQZ1m_-pu4CdpC7TZ4mO09PsSV1zhD6CFfBxpUmDUyWdf9guzJe3hkqa-ckUvuVNr9lxMEzgaoauYQFqQ-cbo91s6WZXmY4bEV9yorfv4_PewROa8iuquqyb97C1uFmGD-j1LNwEHqqpmsCj_aOL7z_w6vD02yT_9H8BSFkEvQ |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interpreting+success+or+failure+of+peanut+oral+immunotherapy&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Cao%2C+Shijie&rft.au=Nagler%2C+Cathryn+R&rft.date=2022-01-18&rft.issn=1558-8238&rft.eissn=1558-8238&rft.volume=132&rft.issue=2&rft_id=info:doi/10.1172%2FJCI155255&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1558-8238&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1558-8238&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1558-8238&client=summon |